Brought to you by 
Mylan gets rights to Pfizer's dry powder inhaler platform
07 Dec 2011
Executive Summary
Pfizer Inc. has licensed generics giant Mylan Inc. exclusive rights to develop, manufacture, and commercialize its generic equivalents of GlaxoSmithKline PLC's Advair/Seretide Diskus products, which deliver fixed-dose combinations of fluticasone propionate and salmeterol via a dry powder inhaler to treat asthma and chronic obstructive pulmonary disorder (COPD).
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Pulmonary
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mylan gets rights to Pfizer's dry powder inhaler platform
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice